Release Details

TRACON to Report Second Quarter 2015 Company Highlights and Financial Results on August 5, 2015

July 29, 2015

SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its second quarter 2015 financial and operating results after the close of U.S. financial markets on Wednesday, August 5, 2015. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:
Date: August 5, 2015
Time: 4:30 pm Eastern Daylight Time (1:30 pm Pacific Daylight Time)
Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode: 93406510
Via web: www.traconpharma.com; "Events and Presentation" section within the "Investors" section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

CONTACT: Company Contact:
         Casey Logan
         Chief Business Officer
         (858) 550-0780 ext. 236
         clogan@traconpharma.com

         Investor Contact:
         Andrew McDonaldLifeSci Advisors LLC
         646-597-6987
         Andrew@lifesciadvisors.com

Tracon Pharmaceuticals, Inc. Logo

TRACON Pharmaceuticals, Inc.